Published in J Clin Microbiol on July 01, 2004
Significant gene order and expression differences in Bordetella pertussis despite limited gene content variation. J Bacteriol (2006) 1.48
Strain variation among Bordetella pertussis isolates in finland, where the whole-cell pertussis vaccine has been used for 50 years. J Clin Microbiol (2005) 1.28
Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J Clin Microbiol (2005) 1.23
Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains. Clin Vaccine Immunol (2007) 1.14
Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J Clin Microbiol (2007) 1.04
Changes in the genomic content of circulating Bordetella pertussis strains isolated from the Netherlands, Sweden, Japan and Australia: adaptive evolution or drift? BMC Genomics (2010) 1.04
Genome Structural Diversity among 31 Bordetella pertussis Isolates from Two Recent U.S. Whooping Cough Statewide Epidemics. mSphere (2016) 1.02
Effect of vaccination on Bordetella pertussis strains, China. Emerg Infect Dis (2010) 0.98
Use of monoclonal antibodies to serotype Bordetella pertussis isolates: comparison of results obtained by indirect whole-cell enzyme-linked immunosorbent assay and bacterial microagglutination methods. J Clin Microbiol (2005) 0.93
SNP-based typing: a useful tool to study Bordetella pertussis populations. PLoS One (2011) 0.93
The First Macrolide-Resistant Bordetella pertussis Strains Isolated From Iranian Patients. Jundishapur J Microbiol (2014) 0.89
Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009. J Clin Microbiol (2012) 0.86
Antigenic divergence of Bordetella pertussis isolates in Taiwan. J Clin Microbiol (2005) 0.83
Appearance of macrolide-resistant Bordetella pertussis strains in China. Antimicrob Agents Chemother (2013) 0.83
Strain variation among Bordetella pertussis isolates circulating in Poland after 50 years of whole-cell pertussis vaccine use. J Clin Microbiol (2011) 0.82
Pulsed-field gel electrophoresis characterization of Bordetella pertussis clinical isolates circulating in Turkey in 2001-2009. Eur J Clin Microbiol Infect Dis (2011) 0.80
Genetic Profile Variation in Vaccine Strains and Clinical Isolates of Bordetella pertussis Recovered from Iranian Patients. Avicenna J Med Biotechnol (2014) 0.76
A Proteomic Characterization of Bordetella pertussis Clinical Isolates Associated with a California State Pertussis Outbreak. Int J Proteomics (2015) 0.76
Changes in Predominance of Pulsed-Field Gel Electrophoresis Profiles of Bordetella pertussis Isolates, United States, 2000-2012. Emerg Infect Dis (2016) 0.76
Increase in pertussis cases along with high prevalence of two emerging genotypes of Bordetella pertussis in Perú, 2012. BMC Infect Dis (2016) 0.75
Isolation of High Level Macrolide Resistant Bordetella pertussis Without Transition Mutation at Domain V in Iran. Jundishapur J Microbiol (2015) 0.75
Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol (1995) 88.05
Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat Genet (2003) 9.13
A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med (1996) 5.07
Use of pulsed-field gel electrophoresis for epidemiological study of Bordetella pertussis in a whooping cough outbreak. J Clin Microbiol (1994) 4.13
Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun (1998) 3.76
Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis (1999) 3.48
Epidemiological typing of Bordetella pertussis isolates: recommendations for a standard methodology. Eur J Clin Microbiol Infect Dis (2000) 3.09
Pertussis of adults and infants. Lancet Infect Dis (2002) 2.95
Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerg Infect Dis (1997) 2.32
Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J Infect Dis (2000) 2.05
Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J Clin Microbiol (2002) 2.02
Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol (2001) 2.02
Pertussis notifications in Australia, 1991 to 1997. Commun Dis Intell (1997) 1.93
Changes in predominance and diversity of genomic subtypes of Bordetella pertussis isolated in the United States, 1935 to 1999. Emerg Infect Dis (2002) 1.58
Placebo-controlled trial of two acellular pertussis vaccines in Sweden--protective efficacy and adverse events. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet (1988) 1.55
Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland. Vaccine (2001) 1.42
Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine (2003) 1.29
Molecular epidemiology of Bordetella pertussis by pulsed-field gel electrophoresis profile: Cincinnati, 1989-1996. J Infect Dis (2001) 1.29
Analysis of Bordetella pertussis isolates from an epidemic by pulsed-field gel electrophoresis. J Clin Microbiol (1995) 1.15
Genomic plasticity in natural populations of Bordetella pertussis. J Bacteriol (1999) 1.09
Subtyping of foodborne and environmental isolates of Escherichia coli by multiplex-PCR, rep-PCR, PFGE, ribotyping and AFLP. J Microbiol Methods (2003) 1.07
A comparison of the DNA fragment patterns of the mouse-virulent challenge strains and clinical isolates of Bordetella pertussis. J Infect (1993) 1.00
Strain variation among Bordetella pertussis isolates from Québec and Alberta provinces of Canada from 1985 to 1994. J Clin Microbiol (2003) 0.97
Application of pulsed field gel electrophoresis to the 1993 epidemic of whooping cough in the UK. Epidemiol Infect (1995) 0.94
Seroepidemiology of Bordetella pertussis infections in the Spanish population: a cross-sectional study. Vaccine (2000) 0.94
Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. Clin Infect Dis (2002) 0.93
Bordetella pertussis serotype of clinical isolates in Sweden during 1970-1995 and influence of vaccine efficacy studies. Dev Biol Stand (1997) 0.93
Reproducibility of Bordetella pertussis genomic DNA fragments generated by XbaI restriction and resolved by pulsed-field gel electrophoresis. J Clin Microbiol (2002) 0.91
Fimbrial typing of Bordetello pertussis isolates: agglutination with polyclonal and monoclonal antisera. J Clin Microbiol (2001) 0.84
Strain variation among Bordetella pertussis isolates in finland, where the whole-cell pertussis vaccine has been used for 50 years. J Clin Microbiol (2005) 1.28
Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J Clin Microbiol (2005) 1.23
Multiple-primer DNA sequencing method. Electrophoresis (2003) 1.21
Pertussis vaccination in infancy lowers the incidence of pertussis disease and the rate of hospitalisation after one and two doses: analyses of 10 years of pertussis surveillance. Vaccine (2011) 1.11
Population dynamics of Bordetella pertussis in Finland and Sweden, neighbouring countries with different vaccination histories. Vaccine (2006) 1.04
Clinical outcome of pertussis in Sweden: association with pulsed-field gel electrophoresis profiles and serotype. APMIS (2007) 0.98
European Sero-Epidemiology Network 2: standardisation of immunoassay results for pertussis requires homogeneity in the antigenic preparations. Vaccine (2008) 0.93
Use of monoclonal antibodies to serotype Bordetella pertussis isolates: comparison of results obtained by indirect whole-cell enzyme-linked immunosorbent assay and bacterial microagglutination methods. J Clin Microbiol (2005) 0.93
Legionella pneumophila serogroup 1 antibody kinetics in patients with Legionnaires' disease: implications for serological diagnosis. Scand J Infect Dis (2003) 0.88
Changes of the Swedish Bordetella pertussis population in incidence peaks during an acellular pertussis vaccine period between 1997 and 2004. APMIS (2007) 0.88
Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model. Vaccine (2005) 0.88
Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine. Pediatr Infect Dis J (2002) 0.87
Pertussis vaccines: where to now? Expert Rev Vaccines (2011) 0.82
Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules. Expert Rev Vaccines (2011) 0.82
[The Swedish child vaccination program also reaches the children born abroad. Serologic samples show good protection compared to Swedish-born]. Lakartidningen (2012) 0.75